EUVIMEDEUVIMED entdecken
Crossref

Qualified kidney injury biomarkers demonstrate value during early clinical drug development

Kodihalli C Ravindra iD, Kelly A Fader iD, David Potter, Zaher A Radi, Gary S Friedman, Karrie A Brenneman, Neeta B Amin, Roberta Weiss, Spencer I Danto, Karen Page, Shashi K Ramaiah, Vishal S Vaidya

Toxicological Sciences · 2024

DOI: 10.1093/toxsci/kfae088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Kodihalli C Ravindra und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States. Hauptthemen laut MEDLINE: Biomarkers, Drug Development, Acute Kidney Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced kidney injury (DIKI) is of significant concern, both during drug development and in clinical practice. We report a patient-centric approach for clinical implementation of the FDA-qualified kidney safety biomarker panel, highlighting Phase 1 and 2 trials for candidate therapeutics in Pfizer’s portfolio (PFE-1 and PFE-2, respectively) that induced kidney tubular injury in rat toxicity studies. Clusterin (CLU), cystatin-C (CysC), kidney injury molecule-1 (KIM-1), N-acetyl-beta-d-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), and osteopontin (OPN) were measured in urine samples from (i) Phase 1 healthy volunteers (HVs; n = 12) dosed with PFE-1, (ii) Phase 2 rheumatoid arthritis (RA) patients (n = 266) dosed with PFE-2, (iii) lupus patients on standard-of-care therapies (n = 121), and (iv) healthy volunteers (n = 60). The FDA-defined composite measure (CM), calculated as the geometric mean response across the 6 biomarkers, was increased ∼30% in HVs administered 100 mg PFE-1 relative to placebo, providing evidence of DIKI. In contrast, the CM for RA patients dosed with PFE-2 was comparable to placebo controls, helping to de-risk the concern for DIKI at clinically relevant doses. Comparing individual biomarker concentrations across disease states revealed that CLU, KIM-1, NAG, NGAL, and OPN are elevated in the urine of RA and lupus patients (those without severe active proliferative lupus nephritis) relative to HVs. Overall, these case studies demonstrate the value of using the FDA-qualified kidney biomarker panel to guide risk assessment, dose selection, and clinical decision making for novel therapeutics, both in HVs and patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersDrug DevelopmentAcute Kidney InjuryHumansAnimalsMaleFemaleArthritis, RheumatoidMiddle AgedAdultOsteopontinHepatitis A Virus Cellular Receptor 1Rats

Stichwörter der Autor:innen

kidney toxicitykidney tubular injuryqualified biomarkerssafety de-risking

Substanzen

BiomarkersOsteopontinHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1

Autor:innen und Institutionen

  • Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States.
  • Department of Translational Clinical Sciences, Pfizer Inc., Groton, CT 06340, United States.
  • Department of Global Biometrics and Data Management, Pfizer Inc., Cambridge, MA 02139, United States.
  • Department of Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, United States.
  • Department of Inflammation and Immunology, Pfizer Inc., Collegeville, PA 19426, United States.
  • Department of Internal Medicine, Pfizer Inc., Cambridge, MA 02139, United States.

ORCID-Profile: Kodihalli C Ravindra, Kelly A Fader

Zitieren

APA

Ravindra, K. C., Fader, K. A., Potter, D., Radi, Z. A., Friedman, G. S., Brenneman, K. A., Amin, N. B., Weiss, R., Danto, S. I., Page, K., Ramaiah, S. K., & Vaidya, V. S. (2024). Qualified kidney injury biomarkers demonstrate value during early clinical drug development. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae088

Vancouver

Ravindra KC, Fader KA, Potter D, Radi ZA, Friedman GS, Brenneman KA, et al. Qualified kidney injury biomarkers demonstrate value during early clinical drug development. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae088

BibTeX
@article{Ravindra2024,
  author = {Ravindra, Kodihalli C and Fader, Kelly A and Potter, David and Radi, Zaher A and Friedman, Gary S and Brenneman, Karrie A and Amin, Neeta B and Weiss, Roberta and Danto, Spencer I and Page, Karen and Ramaiah, Shashi K and Vaidya, Vishal S},
  title = {Qualified kidney injury biomarkers demonstrate value during early clinical drug development},
  journal = {Toxicological Sciences},
  year = {2024},
  doi = {10.1093/toxsci/kfae088}
}
Kostenlos starten →